Intercept could net $62.9m at middle of IPO price range
This article was originally published in Scrip
Intercept Pharmaceuticals set preliminary pricing on 27 September for its initial public offering at $13 to $15 per share, which will give the New York-based company $62.9 million in net proceeds if all 4.3 million shares of common stock plus 645,000 additional shares are sold at the mid-point of the initial price range.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.